Soligenix halts phase three HyBryte trial for cutaneous T-cell lymphoma due to futility
Updated
Updated · MarketWatch · Apr 28
Soligenix halts phase three HyBryte trial for cutaneous T-cell lymphoma due to futility
8 articles · Updated · MarketWatch · Apr 28
The company announced the trial was stopped after 18 weeks, with $5.9 million in cash remaining and plans to analyze the data.
CEO Christopher Schaber stated that, unlike previous studies, the current trial did not show significant lesion reduction, prompting a review of strategic options including mergers or advancing dusquetide for Behcet's Disease.
Dusquetide has recently received orphan drug designation from the European Medicines Agency, and Soligenix will assess future directions in light of the trial's failure.
After HyBryte's collapse, can Soligenix's backup drug for Behçet's Disease prevent a total corporate failure?
With only $5.9 million in cash, is Soligenix now a prime acquisition target for larger pharma rivals?
Why did a promising skin cancer therapy that succeeded in earlier trials suddenly fail its final test?
Could flawed trial design, not the drug itself, be the real reason for HyBryte's shocking futility?
Does this high-profile failure prove the clinical trial model for rare diseases is fundamentally broken?